November 18th, 2024: Ratio Enters License and Collaboration …

5 days ago · Ratio to to receive upfront, and potential milestones and tiered royalty payments. BOSTON, November 18, 2024 /PRNewswire/ — Ratio Therapeutics Inc. (Ratio), a …

CouponFollow Extension

$745
OFF

Novartis Strengthens Radiopharma Leadership With Ratio …

6 days from now

Novartis has teamed up with Ratio Therapeutics in a $745m licensing and collaboration agreement to advance radiopharmaceutical therapies. ... partnering with US-based startup …

msn.com

$745
OFF

Ratio Therapeutics Lands $745M Cancer Drug Development Deal …

6 days from now

5 days ago · Ratio Therapeutics has entered into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG to develop a Somatostatin Receptor 2 (SSTR2) …

stocktitan.net

$745
OFF

Novartis Continues Push Into Radiopharma With $745M Ratio Deal

6 days from now

5 days ago · With two approved radioligand therapies on its commercial roster and a recent plan to boost its manufacturing for radiotherapeutics, Novartis AG tapped Ratio Therapeutics Inc. in …

bioworld.com

$750
OFF

Ratio Nets Potential $750M Radioligand Cancer Deal With Novartis

6 days from now

4 days ago · Ratio Therapeutics has inked an exclusive worldwide agreement potentially worth $745M with Novartis Pharma AG. The collaboration leverages Ratio’s radioligand therapy …

insideprecisionmedicine.com

$745
OFF

Novartis Inks $745M Radiopharma Partnership With Ratio …

6 days from now

4 days ago · Novartis secured a $745 million partnership with radiopharmaceutical biotech Ratio Therapeutics to develop a cancer candidate, the companies announced Monday morning. …

mmm-online.com

$745
OFF

Novartis Strikes Radiopharma Deal With Ratio Worth Up To $745M

6 days from now

4 days ago · Novartis and Ratio Therapeutics announced a collaboration deal worth up to $745 million, focusing on SSTR2 radiotherapeutic cancer treatment. Ratio will receive an …

endpts.com

$745
OFF

Ratio Therapeutics Partners With Novartis For $745M... | DeepNewz

6 days from now

3 days ago · Ratio Therapeutics has entered into an exclusive worldwide license and collaboration agreement with Novartis, potentially valued at $745 million, to develop a radiotherapeutic …

deepnewz.com

FAQs about November 18th, 2024: Ratio Enters License and Collaboration … Coupon?

Does Novartis have a partnership with ratio Therapeutics?

Novartis (NYSE:NVS) has entered into an exclusive worldwide license and collaboration agreement with Ratio Therapeutics for the development of a SSTR2 radiotherapeutic candidate for the treatment of cancer. Under the deal, Ratio will receive up to $745M in upfront and potential milestone payments, plus tiered royalties on future sales. ...

Is N ovartis partnering with ratio Therapeutics?

N ovartis (NYSE: NVS) has entered into an exclusive worldwide license and collaboration agreement with Ratio Therapeutics for the development of a SSTR2 radiotherapeutic candidate for the treatment of cancer. Under the deal, Ratio will receive up to $745M in upfront and potential milestone payments, plus tiered royalties on future sales. ...

Who is ratio Therapeutics (ratio)?

Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS). ...

How much money will ratio receive from Novartis?

Under the terms of the agreement, Ratio will receive combined upfront and potential milestone payments up to $745m, and is eligible to receive tiered royalty payments. Ratio will collaborate with Novartis to drive preclinical activities to research and select an SSTR2-targeting development candidate. ...

Is ratio partnering with Novartis to develop a new sstr2-targeting therapy?

"The team at Ratio is honored and excited to partner with Novartis on the development of a next-generation SSTR2-targeting therapeutic," said Jack Hoppin, Ph.D., Chief Executive Officer of Ratio. "Together, we aim to develop a best-in-class therapy in the fight against SSTR2-expressing tumors." ...

What is Novartis doing with radioligand therapy?

In the announcement accompanying the deal, Novartis’ president of biomedical research Fiona Marshall said: “Radioligand therapies hold transformative potential for certain forms of cancer, and Novartis is committed to maximising their impact by continually improving the benefit for patients.” ...